Arimoclomol

MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for: MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older.

Side effects, and when to stop

The following clinically significant adverse reactions are described below and elsewhere in the labeling:

Hypersensitivity Reactions.
Increased Creatinine without Affecting Glomerular Function.

Who should not take it

None.

Cite this page

NLM: sofidex [Internet]. Daloreum; c2026. Arimoclomol; [reviewed 2026 Aug 2; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/arimoclomol
APA 7th: sofidex. (2026, August 2). Arimoclomol. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/arimoclomol
AMA 11th: Arimoclomol. sofidex. Reviewed August 2, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/arimoclomol

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.